These studies were undertaken to investigate the selectivity of cortical muscarinic receptor radioligand binding in muscarinic M 1 and M 4 receptor knockout mice and to determine whether a marked decrease in 3 H]pirenzepine binding in BA 9 from a subset of people with schizophrenia is predictive of decreases in muscarinic receptors in other CNS regions. However, there were some region-specific decreases in muscarinic receptors in tissue from people with schizophrenia who were outside this subset. These data add to a growing body of evidence suggesting there are widespread decreases in muscarinic receptors in the CNS of some subjects with schizophrenia, as demonstrated by neuroimaging. Our data have implications for understanding the potential clinical utility of drugs directed at the orthosteric and allosteric sites of muscarinic receptors to treat schizophrenia.
Introduction
It has been suggested that developing new drugs to treat psychiatric disorders will require an increased understanding of their pathophysiologies (Insel, 2009) . Given that schizophrenia (Sz) is now recognized as a syndrome of disorders with multiple aetiologies (Tamminga, 2008) , an important step in understanding its pathophysiologies will be to dissect the syndrome into component disorders. It is therefore pertinent that we recently reported that approximately 25 % of subjects with Sz could be separated into a distinct subgroup (CHRM-Sz) based on a marked loss (y75 %) of [ 3 H]pirenzepine binding sites in Brodmann's area (BA) 9 ). Importantly, due to the conditions under which we measure [ 3 H]pirenzepine binding, our data strongly suggested that the decrease in radioligand binding was due to a loss of muscarinic M 1 receptors (CHRM1) . A widespread loss of CHRMs was first reported in the central nervous system (CNS) of drugfree subjects with Sz using single-photon emission computed tomography (Raedler et al. 2003) . Now, our post-mortem data suggest such losses may be restricted to people with CHRM-Sz, making these people vulnerable to a loss of regionally controlled behaviours (Bush et al. 2000 ; Koechlin et al. 2003 ) regulated through muscarinic receptors (Felder et al. 2001 ; Greba et al. 2000) . Recent data have cast doubt on the specificity of currently available CHRM antibodies because they fail to pass certain quality control criteria (Pradidarcheep et al. 2008) . This suggests that the use of radioligands, which themselves show varying specificity for CHRM depending on a variety of methodological conditions (Dorje et al. 1991) , will remain a front line tool for studying the distribution of CHRM in the CNS. Hence, in this study we have used tissue from CHRM1
x/x and CHRM4
x/x to better understand the receptor selectivity of the three radioligands that are commonly used to study CHRM in the CNS under the methodological conditions used in our previous studies Gibbons et al. 2009 ). Thus, this study was undertaken to : (i) determine whether people with CHRM-Sz have widespread losses in [
3 H]pirenzepine binding of similar orders of magnitude in multiple CNS regions, (ii) to determine whether changes in the binding of other muscarinic receptor selective radioligands are also selectively affected in CHRM-Sz and (iii) to obtain further data on the specificity of each radioligand used in this study by measuring its binding density in the cortex of CHRM1
x/x , CHRM4
x/x and wild-type (WT) mice.
Method

Ethical approval
Approval to collect human tissue was obtained from the Ethics Committee of the Victorian Institute of Forensic Medicine with permission to collect tissue being obtained from the closest next of kin. Permission to use the tissue for the studies described was from the Mental Health Research and Ethics Committee of Melbourne Health. Approval for the use of animals for these studies was from the Animal Ethics Committee of the Florey Neurosciences Institute.
Tissue collection
All human tissue was sourced through the Victorian Brain Bank Network, Mental Health Research Institute, Parkville, Australia. Thus, following agreed protocols, CNS tissue was collected from people who had been seen alive up to 5 h prior to being found dead and where cadavers had been refrigerated within 5 h to ensure slowing of any autolysis of the CNS (Ferrer et al. 2007) . To further ensure optimum CNS preservation, each hemisphere was processed in a standardized manner to guarantee that the tissue was frozen to x70 xC within 30 min of autopsy .
To ascertain whether the tissue had suffered excessive autolytic damage, CNS pH was measured as described previously (Kingsbury et al. 1995) as this is now recognized as giving a much better indication as to the quality of tissue preservation, which is often not related simply to post-mortem interval (PMI ; Stan et al. 2006) . RNA integrity numbers were not obtained for this study as they provide no additional value in tissue quality assessment for studies focused on proteins (Stan et al. 2006) . Finally, for each case, PMI was calculated as the time between witnessed death and autopsy or the midpoint between the subject being found and being last seen alive and autopsy.
Studies on the specificity of radioligand binding
While we have previously published data on the selectivity of [ 3 H]pirenzepine binding under the assay conditions we developed , we wanted to continue to develop a better understanding of the selectivity of different radioligands for CHRMs. To this end, we undertook radioligand binding studies on frontal cortex from 10 CHRM1
x/x mice, nine CHRM4
x/x mice and 10 WT controls (gift from Lilly
Research Laboratories, USA) generated as described previously (Gomeza et al. 1999 ; Porter et al. 2002) . This tissue was taken from mice that were killed by cervical dislocation and that had been rapidly frozen to x70 xC immediately following dissection.
Studies on Sz
The collection of tissue from specific regions for this study was guided by cytotectonic markers (Garey, 1999) . Tissue was collected from BA 9 (lateral surface of the frontal lobe including the middle frontal gyrus superior to the inferior frontal sulcus), BA 10 (most rostral portions of the superior frontal gyrus and middle frontal gyrus, bounded ventrally by the superior rostral sulcus), BA 24 (anterior cingulate gyrus around the genu of the corpus callosum), BA 44 (the region occupying the opercular region of the inferior frontal gyrus, bounded rostrally by the ascending limb of the lateral sulcus and caudally by the inferior precentral sulcus) and BA 46 (lateral surface of the frontal lobe and including approximately the middle third of the middle frontal gyrus) from 38 people with Sz and 20 people with no history of psychiatric illness (controls). All of the cases were part of the cohorts used in the study that first identified a subgroup of subjects with Sz who had a marked loss of CHRM1 in BA 9 ). Of the 38 people with Sz, 18 people were diagnosed as having Sz but were part of the subgroup that had levels of cortical CHRM1 equivalent to that observed in control subjects (CHRM+Sz) whilst 20 people had CHRM-Sz. The diagnosis of Sz was made by a senior psychologist and a psychiatrist after an extensive case history review using the Diagnosis for Brain Studies according to DSM-IV criteria (Roberts et al. 1998) . The cases to be studied were closely matched for sex and age to minimize the impact of these factors as potential confounding variables (Supplementary  Table S1 ) so there were no significant differences in these variables between people with Sz and the controls (sex : p=1.00, age : p=0.88) or between people with Sz with CHRM-Sz, CHRM+Sz and the controls (sex : p=0.98, age : F=0.022, d.f.=2,55, p=0.98).
In situ radioligand binding with autoradiography Using a cryostat, 20 mm frozen sections were cut from human BA 9, BA 46, BA 10, BA 24 and BA 44, as well as murine frontal lobes, and thaw mounted on to gelatinized slides. 3 H]4-DAMP binding assays were performed using single point saturation methods, as described previously (Gibbons et al. 2009 ; Supplementary Table S2 : all radioligands were purchased from PerkinElmer, USA) which give good estimations of total number of available binding sites in a tissue section (Pavey et al. 2002) along with the anatomical distribution of that radioligand binding.
The binding of each radioligand was measured in the absence (total binding : three sections) and presence of a competing displacing agent (non-specific binding : two sections). Fixed sections were apposed to a BAS-TR2025 plate (Fujifilm, Japan) with [
3 H]microscales TM (Amersham Biosciences, UK). All plates were scanned in a BAS5000 high resolution phosphoimager (Fujifilm). The resulting images were analysed using AIS imaging software (Imaging Research, Canada) and the intensity of images measured. To determine if there was any systematic variability in radioligand binding across the software, a transept was placed across each cortical autoradiograph. In the areas of cortical regions where systematic variations in radioligand binding were identified, the intensity of each discrete layer of binding was measured and the cortical laminae included in these layers identified by comparing autoradiographs with the same section stained with Cresyl Violet (see below). The intensity readings from each image were then converted to fmol/mg estimated tissue equivalents by comparing the reading from each region to a standard curve of standardized radioactivity on calibrated microscales. Specific binding was then calculated by subtracting the average non-specific binding value from total binding.
Cresyl Violet staining
To determine the cyto-anatomical detail encompassed within a layer of radioligand binding, each autoradiograph was compared to the section from which the autoradiograph was generated after the section had been stained with Cresyl Violet. Cresyl Violet staining was performed as described previously ) after the autoradiographic image had been generated. Thus, sections were fixed in 10 % formalin in phosphate buffered saline for 1 h at room temperature (RT). Sections were immersed in 0.1 % Cresyl Violet in 1 % acetic acid for 15 min at 37 xC and then rinsed in dH 2 O. Slides were immersed for 1 min twice in ethanol and then twice in xylene substitute for 1 min at RT. Sections were mounted in DPX and imaged using a light microscope with a digital camera attached.
Statistics
All data were first interrogated with the d'Agostino & Pearson omnibus normality test as this is best at determining data distribution in small cohorts (d 'Agostino et al. 1990 ).
Student's t test was used to identify significant differences between numerical demographic and CNS collection data between Sz and the controls. The same test was used to compare numeric illness and pharmacologically related data from people with CHRMSz and CHRM+Sz. One-way analysis of variance (ANOVA) was used when comparing demographic and CNS collection data between CHRM-Sz, CHRM+Sz and controls. All non-numerical data, such as gender frequency, were compared using the Fisher's exact test. Variance in data across diagnosis or receptor binding status and between CNS regions was identified using a two-way ANOVA and the source of the variation identified with a post-hoc Bonferroni's test.
The potential impact of autolytic processes that follow death vary on a protein-to-protein basis (Ferrer et al. 2007 ) and therefore the effect of potential confounds is best identified by seeking to identify relationships between experimental measures and those confounds. Thus, Pearson's product moment correlations were used to identify any relationships between radioligand binding and potential confounding variables. To avoid over-interpretation, evidence of a strong relationship between variables was taken at r 2 >0.70 (Cook & Weisberg, 2011 ) and for such relationships, an analysis of covariance was completed. Finally, variance in radioligand binding between mouse CNS (CHRM1
x/x mice, CHRM4
x/x mice and WT) was identified with a one-way ANOVA and Bonferroni's test. Where data were shown to have a non-binomial distribution equivalent, non-parametric analyses were completed.
All analyses were conducted using Prism 5.01 (GraphPad Software, USA) except the General Linear Model (Minitab 15 ; Minitab Inc., USA).
Results
Studies on the specificity of radioligand binding
All radioligand binding data from CHRM1
x/x and WT mice approximated to a Gaussian distribution.
There was a variance in the binding of
x/x and WT mice (F=65.6, d.f.=2,26, p<0.0001) due to a significant decrease (89 %) in radioligand binding to the cortex of CHRM1 x/x mice compared to WT mice while cortical binding in CHRM4 x/x did not differ from WT (Fig. 1 a) .
There was a variance in the binding of [ 3 H]AF-DX 384 to the cortex of CHRM1
x/x and WT mice (F=28.7, d.f.=2,26, p<0.0001) due to significant decreases in radioligand binding to the cortex of CHRM1 x/x and CHRM4 x/x mice (23 and 25 % respectively) compared to that in WT (Fig. 1 b) .
There was a variance in the binding of [ 3 H]4DAMP to the cortex of CHRM1
x/x and WT mice (F=43.1, d.f.=2,26, p<0.0001) due to a significant decrease in radioligand binding to the cortex of CHRM1 x/x and CHRM4 x/x (56 and 35 % respectively) mice compared to WT (Fig. 1 c) . Radioligand binding in Sz :
The binding of [ 3 H]pirenzepine did not show any systematic variation across cortical laminae in BA 10 and BA 46. By contrast, two significantly different levels of radioligand binding could be detected in BA 44 with the outer layer overlaying cortical laminae I-V (layer 1) and the inner layer being restricted to lamina VI (layer 2). The distribution of [ 3 H]pirenzepine binding was complex and did not show a Gaussian distribution in all CNS regions. Thus, these data were analysed using the generalized linear model as this approach is most appropriate in identifying variance in datasets of mixed distribution (McCullagh & Neider, 1989 ). Bonferroni's post-hoc analyses were used to identify the source of any variance in binding. There was significant variation in radioligand binding with both diagnosis (F=174, d.f.=1,5,332, pf0.0001) and CNS region (F=41, d.f.=5,1,332, p<0.001 ; Fig. 2a did not vary across cortical laminae in BA 10 and BA 46 but showed two distinct layers of binding in BA 9 and BA 44. Significantly, in both regions, the outer layer of binding overlaid cortical laminae I-V (layer 1) and the inner layer were restricted to lamina VI (layer 2).
[ 3 H]4-DAMP showed a complex variation in distribution across CNS regions and diagnostic cohorts and, therefore, the same approach to data analyses used for the other radioligand binding data was employed. Thus, when comparing Sz to controls, there was significant variation in radioligand binding with both diagnosis (F=42, d.f.=1,5,334, pf0.0001) and CNS region (F=34, d.f.=5,1,334, p=0.001 ; Fig. 2 
Discussion
One component in this study addressed the specificity of the binding of three muscarinic receptor radioligands to CHRM1 and CHRM4 by measuring radioligand binding to tissue from CHRM1 x/x and CHRM4 x/x mice. Importantly, the CHRM1 and CHRM4 genes were manipulated in these mice so that no protein product was present in the CNS (Gomeza et al. 1999 ; Hamilton et al. 1997 ) making them suitable models in which to investigate the specificity of radioligand binding to CHRM1 and CHRM4. Hence, the data from this, and our previous study using cloned human CHRM1 and CHRM4 3 H]4DAMP binding in both layers of BA 9, BA 46 and layer 1 of BA 44 from people with CHRM-Sz, whereas binding of this radioligand was not changed in any region from people with CHRM+Sz. These data suggest that the loss of cortical muscarinic receptors may be predominantly limited to people with CHRM-Sz.
Our study also gave important data on the different distribution of radioligand binding in human cortex independent of psychiatric diagnoses. Thus, in the case of [
3 H]pirenzepine, radioligand binding was distributed relatively homogeneously across the laminae in BA 10, 46 and 24 but there were two clearly definable layers of binding in BA 44. [
3 H]AF-DX 386 binding was homogenous across BA 9, 10 and 46 but also showed two clearly definable layers in BA 44.
[
3 H]4DAMP was homogeneous in BA 10 and 46 but was in two distinct layers in BA 9 and 44. The cholinergic system of the human CNS is complex with levels of each of the five muscarinic receptors varying across different CNS regions (Wevers, 2011 Scarr et al. 2009 ), would suggest that CHRM4 levels are lower in lamina VI in human BA 9. These insights into levels of CHRM1 and CHRM4, because of our combined studies of human and murine CNS, are novel but are limited in that we cannot identify which cells expressed CHRMs using in situ radioligand binding with autoradiography. Therefore, studies using immunohistochemical techniques to identify which cells have lost CHRM1 in the cortex of subjects with Sz would add to our knowledge of the potential consequences of the loss of these receptors on CNS function. A fuller understanding of the loss of muscarinic receptors in Sz will be important given the potential impact of muscarinic receptors on cortical development (Shideler & Yan, 2010) , their role in the pathophysiology of Sz (Raedler et al. 2007) and their potential as drug targets to treat the disorder (Conn et al. 2009) . However, such studies must be undertaken with caution because of problems with the specificity of anti-CHRM antibodies (Pradidarcheep et al. 2008) .
This study has confirmed the findings from a single photon emission computerized tomography (SPECT) study in drug-free people with Sz (Raedler et al. 2003) that reported widespread losses of CHRMs in many CNS regions. Importantly, our findings suggest that the loss of CHRMs in the cortex of subjects with Sz is due to a loss of CHRM1 in a subset (25 %) of subjects with the disorder ). Significantly, a close examination of the data from the SPECT study shows that three of 12 (25 %) of the subjects with Sz have levels of CHRMs that are lower than those in any of the control subjects (see fig. 3 in Raedler et al. 2003) . This study has shown that decreases in Like other post-mortem studies (Crook et al. 2001 ; Dean et al. 1996 Dean et al. , 2002 Dean et al. , 2008 Deng & Huang, 2005 ; Scarr et al. 2009 ; Zavitsanou et al. 2004 ) and a neuroimaging study (Raedler et al. 2003) , this study failed to show any relationship between levels of CHRMs and final recorded antipsychotic drug dose. Similarly, studies have failed to show decreases in [
3 H]pirenzepine binding in rats treated with antipsychotic drugs (Cawley et al. 1993 ; Crook et al. 2001 ; Han et al. 2008) . These data support the notion that decreases in cortical CHRM1 in Sz are not simply due to treatment with antipsychotic drugs before death.
This study has also shown a decrease in (Allard et al. 1987 ; Shapiro et al. 1988) . Such a hypothesis is feasible given the differing pharmacology reported for human and rat CHRM1 (Thomas et al. 2010) .
The major finding from this study is that people with CHRM-Sz have widespread, profound changes in CHRM1 in all but one CNS region studied, which agrees with a neuroimaging study that has shown widespread decreases in CHRMs in the CNS of drugfree people with Sz (Raedler et al. 2003) . Moreover, our current and previous studies have indicated that our careful manipulation of the conditions under which we measure [
3 H]pirenzepine binding means that our results are essentially a measure of CHRM1, at least in the cortex. Hence, it would appear that people with CHRM-Sz have marked decreases in CHRM1 in BA 10 (frontal pole), BA 46 [dorsolateral prefrontal cortex (DLPFC)], BA 44 layer 1 and 2 (frontal cortex) and BA 24 (anterior cingulate cortex), as well as BA 9 (DLPFC ; Scarr et al. 2009) . We have already shown that G-protein recruitment by the cortical CHRM1 is altered in subjects with CHRM-Sz (Salah-Uddin et al. 2009) ; therefore, these changes in receptor levels are likely to have a functional consequence in CHRM-Sz. Importantly, CHRM1 has critical roles in maintaining mammalian cortical development (Shideler & Yan, 2010) and function (Anagnostaras et al. 2003) and such a profound loss of this receptor in CNS regions that control important CNS functions [frontal pole -reasoning, problem-solving and multi-tasking (Koechlin, 2011) , DLPFC and frontal cortex -executive function and perceptual context (Koechlin et al. 2003) , anterior cingulate -motor control, cognition, arousal/ drive state (Paus, 2001 ) and emotion (Bush et al. 2000) ] means that people with CHRM-Sz are likely to have significant functional impairments.
In conclusion, we (Dean, 2004 ; Felder et al. 2001 ) and others (Conn et al. 2009 ) have postulated that treatment with CHRM agonists could potentially alleviate some of the symptoms of Sz. Our current data would suggest that such treatments could have beneficial effects on a number of CNS functions in CHRMSz, based on the widespread loss of receptors that we now report. This notion is supported by a proof of principal study showing that stimulating muscarinic receptors with the CHRM1/4 selective agonist, xanomeline, decreases the severity of diverse symptoms such as psychoses and cognitive deficits in people with Sz (Shekhar et al. 2008) . Therefore, based on the idea that understanding the pathophysiology of psychiatric disorders will be central to the development of new drugs (Insel, 2009) , our data would support the development of more selective CHRM1 drugs, be they acting at the orthosteric (Sauerberg et al. 1992 ; Tecle et al. 2000) or allosteric (Conn et al. 2009 ; Sams et al. 2010 ) binding site on the receptor. In addition, the development of a functional CHRM1 selective neuroimaging radioligand would be a major advance in identifying people with CHRM-Sz in order to determine if they have either unique symptom or drugresponsive profiles.
Note
Supplementary material accompanies this paper on the Journal's website (http://journals.cambridge.org/ pnp).
